Annual report pursuant to Section 13 and 15(d)

Income Taxes - Additional Information (Detail)

v3.3.1.900
Income Taxes - Additional Information (Detail) - USD ($)
 3 Months Ended 12 Months Ended
Jan. 31, 2016
Jan. 31, 2016
Jan. 31, 2015
Jan. 31, 2014
Income Taxes Disclosure [Line Items]        
Effective tax rate (benefit)/provision   2.00% 4.00% 3.00%
Deferred tax assets, operating loss carry forwards, domestic $ 48,000,000 $ 48,000,000    
Operating loss carry forwards, expiry beginning year   2017    
Deferred tax assets, operating loss carry forwards, state and local 80,800,000 $ 80,800,000    
Deferred tax assets, operating loss carry forwards, foreign 2,000,000 2,000,000    
Deferred tax assets capital loss carry forwards, domestic 13,100,000 $ 13,100,000    
Capital loss carry forwards expiration dates   2018    
Deferred tax assets, tax credit carry forwards, alternative minimum tax 600,000 $ 600,000    
Deferred tax assets, tax credit carry forwards, foreign 2,000,000 2,000,000    
Valuation allowance 47,368,000 47,368,000 $ 30,369,000  
Valuation allowance increased   17,000,000    
Allocation of cumulative undistributed earnings of foreign subsidiaries, reinvestment 82,500,000 82,500,000    
Repatriated amount subject to US tax rate 48,000,000 48,000,000    
Incremental tax benefit   400,000    
Tax benefit recognized for the statute of limitations   325,000 275,000  
Tax benefit recognized for the effect of foreign translation   51,000 329,000  
Significant change in tax positions due to the statute of limitations 400,000 400,000    
Unrecognized tax benefits 5,151,000 5,151,000 $ 5,527,000 $ 6,035,000
Interest on income tax expense   400,000    
State and Local Jurisdiction [Member]        
Income Taxes Disclosure [Line Items]        
Deferred tax assets, tax credit carry forwards, research 3,600,000 3,600,000    
Deferred tax assets tax credit carry forward investment 300,000 300,000    
Federal [Member]        
Income Taxes Disclosure [Line Items]        
Deferred tax assets, tax credit carry forwards, research 1,800,000 $ 1,800,000    
Reduction in federal net operating loss carryforward (2,300,000)      
Increase in federal capital loss carryforward 2,300,000      
Reduction in federal research and development credit $ (100,000)